CYCLOXAN 50MG TABLET contains Cyclophosphamide, which belongs to a group of medicines called Alkylating agents. It is used in the treatment of malignant diseases in adults and children such as malignant lymphomas (Stages III and IV), Hodgkin’s disease, Non-Hodgkin’s lymphoma, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma, multiple myeloma, chronic lymphocytic leukemia, chronic granulocytic leukemia, acute myelogenous and monocytic leukemia, acute lymphoblastic leukemia, mycosis fungoides, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, Ewing’s sarcoma, breast cancer.
CYCLOXAN 50MG TABLET is also indicated for the treatment of nephrotic syndrome in children who fail to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. CYCLOXAN 50MG TABLET is not recommended for use in patients with acute infections, bone-marrow aplasia, urinary tract infections like cystitis, acute urothelial toxicity from cytotoxic chemotherapy or radiation therapy, urinary outflow obstruction, or untreated infections.
Before taking CYCLOXAN 50MG TABLET, inform your doctor if you have allergic or anaphylactic reactions to other alkylating agents, bone marrow suppression or failure include (leukopenia, neutropenia, thrombocytopenia and anaemia), neutropenic fever, serious infections include pneumonias, bacterial, fungal, viral, protozoal, and parasitic infections, severe immune suppression, concomitant chemotherapy and/or radiation therapy, urinary tract and renal diseases like haemorrhagic cystitis, pyelitis, ureteritis, and hematuria, urotoxicity such as bladder ulceration, necrosis, fibrosis, contracture, urinary tract obstructions or active urinary tract infections, nephrotoxicity, including renal tubular necrosis, heart diseases such as myocarditis, myopericarditis, pericardial effusion including cardiac tamponade, and congestive heart failure, ventricular arrhythmias (including atrial fibrillation, flutter, severe QT prolongation with ventricular tachyarrhythmia), pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease, respiratory failure, pneumonitis and secondary malignancies (urinary tract cancer, myelodysplasia, acute leukemias, lymphomas, thyroid cancer, sarcomas, and bladder cancer), veno-occlusive liver disease, poor wound healing, hyponatremia, SIADH (syndrome of inappropriate secretion of antidiuretic hormone), rare hereditary problems of fructose intolerance, galactose intolerance, glucose-galactose malabsorption, Lapp lactase deficiency, sucrase-isomaltase insufficiency, adrenal insufficiency, diabetes and poor general health .
CYCLOXAN 50MG TABLET is not recommended for use by pregnant women. CYCLOXAN 50MG TABLET is generally not recommended for use in breastfeeding women as it may pass through the breast milk. CYCLOXAN 50MG TABLET should be used with caution in children. CYCLOXAN 50MG TABLET should be used with caution in elderly patients aged years or above. The most common side effects of taking CYCLOXAN 50MG TABLET are nausea, vomiting, weight loss, alopecia, hematuria and leukopenia. Contact your doctor if any of your symptoms get worse or persist.